Annual Total Long Term Liabilities
$1.75 B
-$372.23 M-17.53%
31 December 2023
Summary:
Sarepta Therapeutics annual total long term liabilities is currently $1.75 billion, with the most recent change of -$372.23 million (-17.53%) on 31 December 2023. During the last 3 years, it has fallen by -$15.65 million (-0.89%). SRPT annual total long term liabilities is now -17.53% below its all-time high of $2.12 billion, reached on 31 December 2022.SRPT Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Long Term Liabilities
$1.68 B
+$20.68 M+1.25%
30 September 2024
Summary:
Sarepta Therapeutics quarterly total long term liabilities is currently $1.68 billion, with the most recent change of +$20.68 million (+1.25%) on 30 September 2024. Over the past year, it has dropped by -$72.21 million (-4.12%). SRPT quarterly long term liabilities is now -20.93% below its all-time high of $2.12 billion, reached on 31 December 2022.SRPT Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SRPT Long Term Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | -4.1% |
| 3 y3 years | -0.9% | -5.0% |
| 5 y5 years | +136.7% | +127.0% |
SRPT Long Term Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -17.5% | at low | -20.9% | +1.5% |
| 5 y | 5 years | -17.5% | +136.7% | -20.9% | +127.0% |
| alltime | all time | -17.5% | >+9999.0% | -20.9% | >+9999.0% |
Sarepta Therapeutics Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $1.68 B(+1.2%) |
| June 2024 | - | $1.66 B(+0.3%) |
| Mar 2024 | - | $1.65 B(-5.5%) |
| Dec 2023 | $1.75 B(-17.5%) | $1.75 B(-7.5%) |
| Sept 2023 | - | $1.89 B(+0.5%) |
| June 2023 | - | $1.89 B(+4.2%) |
| Mar 2023 | - | $1.81 B(-14.8%) |
| Dec 2022 | $2.12 B(+20.2%) | $2.12 B(+0.1%) |
| Sept 2022 | - | $2.12 B(+23.0%) |
| June 2022 | - | $1.72 B(-1.1%) |
| Mar 2022 | - | $1.74 B(-1.3%) |
| Dec 2021 | $1.77 B(-2.2%) | $1.77 B(-2.9%) |
| Sept 2021 | - | $1.82 B(-1.6%) |
| June 2021 | - | $1.85 B(-0.9%) |
| Mar 2021 | - | $1.87 B(+3.2%) |
| Dec 2020 | $1.81 B(+144.2%) | $1.81 B(+19.6%) |
| Sept 2020 | - | $1.51 B(+1.7%) |
| June 2020 | - | $1.49 B(-0.7%) |
| Mar 2020 | - | $1.50 B(+102.2%) |
| Dec 2019 | $739.87 M(+69.7%) | $739.87 M(+50.6%) |
| Sept 2019 | - | $491.41 M(+1.0%) |
| June 2019 | - | $486.50 M(+1.8%) |
| Mar 2019 | - | $477.96 M(+9.6%) |
| Dec 2018 | $436.11 M(+1.3%) | $436.11 M(+1.7%) |
| Sept 2018 | - | $428.67 M(-3.3%) |
| June 2018 | - | $443.43 M(+2.6%) |
| Mar 2018 | - | $432.33 M(+0.4%) |
| Dec 2017 | $430.42 M(+3489.5%) | $430.42 M(+1218.1%) |
| Sept 2017 | - | $32.66 M(+409.7%) |
| June 2017 | - | $6.41 M(-17.5%) |
| Mar 2017 | - | $7.76 M(-35.3%) |
| Dec 2016 | $11.99 M(-43.3%) | $11.99 M(-12.8%) |
| Sept 2016 | - | $13.75 M(-12.3%) |
| June 2016 | - | $15.68 M(-18.5%) |
| Mar 2016 | - | $19.24 M(-9.0%) |
| Dec 2015 | $21.14 M | $21.14 M(-11.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2015 | - | $23.85 M(-12.9%) |
| June 2015 | - | $27.37 M(+240.3%) |
| Mar 2015 | - | $8.04 M(-23.5%) |
| Dec 2014 | $10.51 M(+25.0%) | $10.51 M(+3.8%) |
| Sept 2014 | - | $10.13 M(+26.9%) |
| June 2014 | - | $7.98 M(-7.9%) |
| Mar 2014 | - | $8.67 M(+3.1%) |
| Dec 2013 | $8.41 M(+246.4%) | $8.41 M(+31.5%) |
| Sept 2013 | - | $6.39 M(+168.8%) |
| June 2013 | - | $2.38 M(-0.9%) |
| Mar 2013 | - | $2.40 M(-1.2%) |
| Dec 2012 | $2.43 M(-11.7%) | $2.43 M(-0.8%) |
| Sept 2012 | - | $2.45 M(-0.9%) |
| June 2012 | - | $2.47 M(-8.6%) |
| Mar 2012 | - | $2.70 M(-1.7%) |
| Dec 2011 | $2.75 M(-6.3%) | $2.75 M(-1.8%) |
| Sept 2011 | - | $2.80 M(-1.6%) |
| June 2011 | - | $2.85 M(-1.6%) |
| Mar 2011 | - | $2.89 M(-1.5%) |
| Dec 2010 | $2.94 M(+1.6%) | $2.94 M(+0.1%) |
| Sept 2010 | - | $2.93 M(-0.9%) |
| June 2010 | - | $2.96 M(-1.8%) |
| Mar 2010 | - | $3.01 M(+4.2%) |
| Dec 2009 | $2.89 M(+14.9%) | $2.89 M(+12.9%) |
| Sept 2009 | - | $2.56 M(+0.7%) |
| June 2009 | - | $2.54 M(+1.2%) |
| Mar 2009 | - | $2.51 M(-0.2%) |
| Dec 2008 | $2.52 M(+0.5%) | $2.52 M(+0.2%) |
| Sept 2008 | - | $2.51 M(+0.1%) |
| June 2008 | - | $2.51 M(-1.7%) |
| Mar 2008 | - | $2.55 M(+1.9%) |
| Dec 2007 | $2.50 M | $2.50 M(+19.9%) |
| Sept 2007 | - | $2.09 M(-0.8%) |
| June 2007 | - | $2.11 M(-2206.7%) |
| Sept 1999 | - | -$100.00 K(-103.2%) |
| Mar 1997 | - | $3.10 M |
FAQ
- What is Sarepta Therapeutics annual total long term liabilities?
- What is the all time high annual total long term liabilities for Sarepta Therapeutics?
- What is Sarepta Therapeutics quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Sarepta Therapeutics?
- What is Sarepta Therapeutics quarterly long term liabilities year-on-year change?
What is Sarepta Therapeutics annual total long term liabilities?
The current annual total long term liabilities of SRPT is $1.75 B
What is the all time high annual total long term liabilities for Sarepta Therapeutics?
Sarepta Therapeutics all-time high annual total long term liabilities is $2.12 B
What is Sarepta Therapeutics quarterly total long term liabilities?
The current quarterly long term liabilities of SRPT is $1.68 B
What is the all time high quarterly long term liabilities for Sarepta Therapeutics?
Sarepta Therapeutics all-time high quarterly total long term liabilities is $2.12 B
What is Sarepta Therapeutics quarterly long term liabilities year-on-year change?
Over the past year, SRPT quarterly total long term liabilities has changed by -$72.21 M (-4.12%)